Affymax, (FRA:A5Y) Change In Payables And Accrued Expense : €-4.04 Mil (TTM As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Affymax, Change In Payables And Accrued Expense?

Affymax,'s Change In Payables And Accrued Expense for the quarter that ended in Jun. 2014 was €-0.29 Mil. It means Affymax,'s Accounts Payable & Accrued Expense declined by €0.29 Mil from Mar. 2014 to Jun. 2014 .

Affymax,'s Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2013 was €-29.07 Mil. It means Affymax,'s Accounts Payable & Accrued Expense declined by €29.07 Mil from Dec. 2012 to Dec. 2013 .

Affymax, Change In Payables And Accrued Expense Historical Data

The historical data trend for Affymax,'s Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Change In Payables And Accrued Expense Chart

Affymax, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

9.71

-17.72

-8.21

6.82

-29.07

Affymax, Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-20.95	-3.12	-0.57	-0.05	-0.29

Affymax, Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.04 Mil.

Affymax, Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Affymax,'s Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax, (FRA:A5Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines